You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

31 search results for: barrier dysfunction

Skin Dysbiosis in AD
expert video

Skin Dysbiosis in AD

Dermatology
Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.
View more
The Role of Type 2 Inflammation in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Dermatology
The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.
View more
Skin <b>Barrier</b>, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.
View more
Targeting Type 2 Inflammation: ​Skin <b>Barrier</b> Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
Skin <b>Barrier</b>, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Dermatology
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
View more
ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases
Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

Type 2 Inflammation
Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care
View more
Connecting Type 2 Inflammation to CRSwNP
expert video

Connecting Type 2 Inflammation to CRSwNP

Rhinology
Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.
View more
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients
expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Pulmonology
Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.
View more
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Pulmonology
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
View more
The Cycle of Inflammation in Adult Asthma
interactivity

The Cycle of Inflammation in Adult Asthma

Pulmonology
Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients
View more
Diving Below the Surface of AD: The Role of Type 2 Inflammation
expert video

Diving Below the Surface of AD: The Role of Type 2 Inflammation

Dermatology
This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.
View more
Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

Dermatology
Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region